Transition looking for diabetes drug partner

Transition Therapeutics is looking for a new business partner, after an arrangement with drug giant Novo Nordisk went sour. Transition need research funding to develop their GLP1-I.N.T therapy. The company work on developing diabetes, Alzheimer’s, multiple sclerosis and hepatitis C treatments .
The islet neogenesis therapy has proved strikingly effective in animal studies according to Transition experts. The therapy works by inducing the generation of new insulin-producing cells. Novo Nordisk retain the rights to another Transition Therapy program, E1-I.N.T, after an investment of $1m.
The failure of the Novo arrangement came due to ‘priorities.’ Transition want to develop GLP1-I.N.T as quickly as possible, with one expert saying: “We needed to move GLP1-I.N.T. into diabetic patients as soon as possible; thus we had no option but to renegotiate the agreement with Novo Nordisk.” Apparently, Novo are now conducting a large phase 3 trial on inhalable insulin.
Transition remains confident that they will have positive news in the near future . The problem likely arose from the need for Transition to push their therapy through development . As a large company, Novo Nordisk could afford to move slower on the development, causing eventual conflict and the break down of the agreement.

To Top